Abstract
A literature search was conducted on studies of new drugs used with patients with schizophrenia reported by U.S. and non-U.S. researchers from 1966–1993, yielding 41 U.S., and a total of 24 other non-U.S. studies, among them 11 British studies. Results of the U.S. and non-U.S. studies were pooled separately and compared. Among several comparable conditions discussed, the lack of any data on suicides in the U.S. studies was observed. For a second statistical analysis of suicide rates ‘person-years’ were calculated to adjust for differing washout durations. The results obtained include findings that the percentage of patients relapsing in U.S. studies was slightly lower (37.9%) than in non-U.S. studies (46%); the percentage of patients dropping out in U.S. studies (10.5%) was higher than in non-U.S. studies (7.6%); known location of dropout patients in U.S. studies was 1.7%, compared to 2.6% in non-U.S. studies. The most interesting finding was that no suicides were reported in U.S. studies, compared to 0.6% of patients reported in British studies. Some U.S. studies used ‘challenge doses’, such as amphetamines or L-dopa; no non-U.S. studies reported their use.
Compared to U.S. studies, those by non-U.S., and particularly British, researchers appeared to report adverse events in their studies. ‘Challenge’ drugs were not used; suicides were reported. It is estimated that the probability that no patients suicided who participated in the U.S. is small—one in 500.
Similar content being viewed by others
References
Shamoo, A.E., Keay, T.J. (1996) Ethical Concerns About Relapse Studies. Cambridge Quarterly of Healthcare Ethics 5:373–386.
Shamoo, A.E., Irving, D.N. (1993) Accountability in research using persons with mental illness. Accountability in Research 3:1–17.
Shamoo, A.E. (1994) Our responsibilities toward persons with mental illness as human subjects in research. J. of the California Alliance for the Mentally Ill 5(5):14–16.
Irving, D.N. (1994) Psychiatric research. Reality check. J of the California Alliance for the Mentally Ill 5(5):42–44.
Shamoo, A.E. (1996) Editor, “Ethics in Neurobiological Research with Human Subjects”, The Baltimore Conference on Ethics held January 7–9, 1995, Baltimore, Maryland, pp. 1–337. Gordon and Breach Science Publishers, New York, N.Y.
Journal of the California Alliance for the Mentally Ill. ‘Ethics in neurobiological research with human subjects’ (series of articles) 1994;5(5):1–69.
Johnson, D.A.W. (1976) The Duration of Maintenance Therapy in Chronic Schizophrenia. Acta Psychiat. Scand. 53:298–301;
Andrews, P. Hall, J.N. and Snaith, R.P. (1976) A Controlled Trial of Phenothiazine Withdrawal in Chronic Schizophrenic Patients. Brit. J. Psychiat 128:451–455;
Stevens, B. (1976) The social value of fluphenazine deconate. Acta psychiat. belg. 76:792–804;
Kingstone, E., Grof, P., Furlong, W., Jacques, W., Vire, L. & Daigle, L. (1977) Penfluridol. A Peroral Long-Acting Neuroleptic, for the Maintenance Treatment of Schizophrenic Patients Who Relapse. J. Clinical Pharmacology 17:252–258;
Dencker, S.J., Lepp, M. & Malm, U. (1980) Clopenthixol and flupenthixol depot preparations in outpatient schizophrenia, I. A one year double-blind study of clophenthixol deconate and flupenthixol palmitate, Acta Psychiat. Scand. (Suppl) 279:10–28;
Dencker, S.J., Lepp, M. & Malm, U. (1980) Do schizophrenic well adapted in the community need neuroleptics? Depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica — Supplementum 279:64–76;
McCredie, R.G., Dingwall, J.M., Wiles, D.H. & Heykants, J.J. (1980) Intermittent pimozide versus fluphenazine decanoate as maintenance. British Journal of Psychiatry 137:510–517;
Capstick, N. (1980) Long-term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients. Acta Psychiatrica Scandinavica 61(3):256–262;
Zander, K.J., Fischer, B., Zimmer, R. & Ackenheil, M. (1981) Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal. Psychopharmacology 73(1):43–47;
Wistedt, B. (1981) A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatric Scandinavica 64(1):65–84;
Cheung, H.K. (1981) Schizophrenic fully remitted on neuroleptics for 3–5 years — to stop or continue drugs? British Journal of Psychiatry 138:490–494;
Odejide, O.A. & Aderounmu, A.F. (1982) Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Journal of clinical psychiatry 43(5):195–196;
McCreadie, R., Mackie, M., Morrison, D. & Kidd, J. (1982) Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry 140:280–286;
Wistedt, B. & Palmstierna, T. (1983) Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. Journal of Clinical Psychiatry 44(10):369–71;
Johnson, D.A., Pasterski, G., Ludlow, J.M., Street, K. & Taylor, R.D. (1983) The discontinuance of maintanence neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatrica Scandinavica 67(5):339–52;
Perenyi, A., Kuncz, E. & Bagdy, G. (1985) Early relapse after sudden withdrawal or dose reduction of clozapine (Letter). Psychopharmacology 86(1–2):244;
Frecska, E., Perenyi, A., Bagdy, G. & Revai, K. (1985) CSF dopamine tumover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment. Psychiatry Research 16(3):221–6;
McMillan, D.E., Fody, E.P., Couch, L., Harrison, R.H., Newton, J.E. & Reese, W.G. (1986) Drug holidays and serum haloperidol levels in schizophrenic patients. Journal of Clinical Psychiatry 47(7):373–4;
Dencker SJ, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatrica Scandinavica, 1986;73(2):181–5;
Fleischhacker, WW., Stuppack, C., Barnas, C., Unterweger, B. & Hinterhuber, H. (1987) Low-dose zotepine in the maintenance treatment of schizophrenia. Pharmacopsychiatry 20(1 Spec No):61–3;
Menkes, D.B., Clarkson, H.O., Caradoc-Davies, G. & Mullen, P.E. (1987) Anticholinergic equivalents and parkinsonism: a model for predicting side-effects of antipsychotic drugs. International Clinical Psychopharmacology 2(1):55–67;
McKane, J.P., Robinson, A.D., Wiles, D.H., McCreadie, R.G. & Stirling, G.S. (1987) Haloperidol decanoate V. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. British Journal of Psychiatry 151:333–6;
Johnson, D.A., Ludlow, JM., Street, K. & Taylor, R.D. (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. British Journal of Psychiatry 151:634–8;
Nishikawa, T., Tanaka, M., Tsuda, A., Koga, I., & Uchida, Y. (1989) Prophylactic effects of neuroleptics in symptoms-free schizophrenia: A comparative dose-response study of timiperone and sulpiride. Biol. Psychiatry 25:861–866;
Soni, S.D., Sampath, G., Shah, A. & Krska, J. (1992) Rationalizing neuroleptic polypharmacy in chronic schizophrenics: Effects of changing to a single depot preparation. Acta Psychiatr. Scand. 85:354–359.
Odejide, O.A. & Aderounmu, A.F. (1982) Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenia patients. J Clin Psychiatry 43(5):195–196.
Johnson, D.A., Ludlow, J.M., Street, D. & Taylor, R.D. (1987) Double-blind comparison of half-dose and standard-dose of flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. British J of Psychiatry 151:634–8.
Inanasga, D., Inoue, K., Tachibana, H., Oshima, M. & Kotoru, T. (1972) Effect of L-dopa in schizophrenia. Folia Psychiatrics et Neurologica Japonica 1972;26(2):145–157. Inanaga K, Nakazawa Y, Inoue K, Tachjibana H, Oshimas M, Kotoru T, Double-blind control study of L-dopa therapy in schizophrenia. Folia Psychiatrie et Neurologica Japonica 29(2):123–143.
Breslow, N.E. & Day, N.E. (1987) Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Internat’l. Agency for Research on Cancer, Lyon, France: 93–4.
Andrews, P., Hall, J.N. & Snaith, R.P. (1976) A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Brit J. Psychiat 128:451–5.
McCreadie, R., Mackie, M., Morrison, D. & Kidd, J. (1982) Once weekly pimozide versus fluphenazine deconoate as maintenance therapy in chronic schizophrenia. Brit J Psychiat 140:280–6.
Capstick, N. (1980) Long-term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients. Acta Psychiat Scand 61:256–262.
Andreasen, N.C. & Carpenter, W.T. (1993) Diagnosis and classification of schizophrenia. Schiz Bull 19:25–40.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. U.S. Department of Health, Education and Welfare Washington, D.C. U.S. Government Printing Office, 1978; The President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Summing up. Washington, D.C.; Government Printing Office, 1983; Office for the Protection of Research Risks. United States Code of Federal Regulation; Protection of Human Subjects 45 CFR 46. Washington, D.C.; U.S. Department of Health, Education and Welfare, 1979 (revised 1983, 1991); The Nurember Code 1947, in: Katz, J. Experimentation with human beings. Russell Sage Foundation, New York, 1992, 305–306; The Declaration of Helsinki 1965 (revised 1975, 1983), in: Katz, J. Experimentation with human beings. ibid 312–313; United Nations Declaration 1991. Principles for the protection of persons with mental illness and for the improvement of mental health care, in: Rosenthal, E. & Rubenstein, I.S. International human rights advocacy under the ‘principles for the protection of persons with mental illness.’ International J of Law and Psychiatry 1993;16:257–3001.
Wyatt, R.J. (1991) Neuroleptics and the natural course of schizophrenia. Schiz Bull 17:325–347.
Miller, R. (1989) Schizophrenia as a progressive disorder. relations in EEG. CT, neuropathological and other evidence. Progress Neurobiology 33:17–44.
Wisiedt, B. (1981) A depot neuroleptic withdrawal study: A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiat Scand 64:65–84.
Johnson, D.A.W., Pasterski, G., Ludlow, J.M., Street, K. & Taylor, R.D.W. (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social sequences. Acta Psychiatr Scand 67:339–352.
Curzon, D.A., Barnes, T.R.E., Bamber, R.W., Platt, S.D., Hirsch, S.R. & Duffy, J.C. (1985) Long Term Depot Maintenance of Chronic Schizophrenic out patients: The Seven Year follow up of the Medical Research Council Fluphenazine/Placebo Trial. I Course of illness, Stability of Diagnosis and the Role of a Special Maintenance Clinic. II The Incidence of Non-Compliance Problems, Side effects, Neurotic Symptoms and Depression. III Relapse Postponement or Relapse Prevention? The Implications for Long Term Outcome. British Journal of Psychiatry 146:464–480.
Temple, R.J. (1994) Special study designs: early escape, enrichment studies in non-responses. Commun Statist — Theory Meth 23(2):499–531.
Declaration of Helsinki op cit; Internation Committee of Medical Journal Editors. Uniform requirements for manuscripts to biomedical journals. N. Engl J Med 324; 424–8.
Appelbaum, P.S., Lidz, C.W. & Meisel, A. (1987) Informed Consent: Legal Theory and Clinical Practice. Oxford University Press, New York, 219f.
Brody, B.B. (1993) Biomedical technology and human rights. Chap 6., UNESCO, Paris, France.
Fletcher, J., Dommel, F. & Crowell, D. (1985) A trial policy for the intramural programs of the National Institutes of Health: consent to research with impaired human subjects. Institutional Review Board 7:1–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shamoo, A.E., Irving, D.N. & Langenberg, P. A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966–1993. SCI ENG ETHICS 3, 395–406 (1997). https://doi.org/10.1007/s11948-997-0043-1
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11948-997-0043-1